

AM

The present application claims priority to US Provisional Patent application serial Number 60/097,210, filed August 20, 1998 and US Provisional Patent application serial number 60/141,169, filed June 25, 1999.

Field of the Invention

The present invention relates generally to the field of cancer treatments, as well as to the field of peptide and non-peptide pharmaceutical compounds.

BACKGROUND OF THE INVENTION

Many lung and prostate cancers, of which small cell lung cancer (SCLC) is a prime example, have a neuroendocrine phenotype, and their growth is stimulated by neuropeptides. Antagonists of several peptides (e.g. bradykinin, substance P, bombesin) have been used in experimental treatment of models of SCLC in animals. Among the most potent of the peptides examined thus far, crosslinked dimers of certain bradykinin antagonist peptides have been efficacious both *in vitro* and *in vivo* against strains of SCLC and other tumors (Chan et al., *Immunopharmacology* 33: 201-204, 1996; Stewart et al., *Can. J. Physiol. Pharmacol.* 75: 719-724, 1997; Stewart et al., US Patent Application 5,849,863, issued 12/15/98). Prostate cancers show a similar neuroendocrine phenotype and are susceptible to neuropeptide antagonists.

SUMMARY OF THE INVENTION

The present invention provides anti-cancer agents (ACA) comprised of a range of novel amino acid derivatives and small peptides having the ability to inhibit growth of SCLC and certain other tumor cell lines (such as non-small cell lung cancer (NSCLC) and prostate cancer) in standard *in vitro* tests, as well as certain monomeric peptides that show inhibition of tumor growth *in vivo*. Certain of the peptides have a general structural relationship to carboxy-terminal

5 fragments of bradykinin antagonists, but the non-peptides show no such general relationship. Monomers, dimers, trimers, tetramers, pentamers and cyclized analogs of the novel molecules are described. The new compounds are tested for bradykinin antagonist activity in standard assays, but there is no apparent relationship between bradykinin antagonist activity and cytolytic potency. All of the molecules described possess both hydrophobic (usually aromatic) and basic
10 groups in their structures. Without being held to one particular theory, it appears that the compounds function by stimulation of cell death (apoptosis) in the tumor cells.

The present invention also provides compounds and methods for inhibiting cancer by administering to a subject afflicted with cancer (ie. of the lung or prostate) a therapeutically effective amount of one or more of the compounds herein described.

In general, the anti-cancer compounds are described by the formula:



wherein X is a linker having 2-5 functional groups or is absent, n = 1-5, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI. Other compounds described herein are defined by the Formula VII. The specifics regarding structure are enumerated in the Detailed Description, Examples and Claims. Certain physical characteristics are enumerated in the Examples as well as the Detailed Description, Examples and Claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows inhibition of growth *in vivo* of SCLC strain SHP-77 by B10054.

25 Figure 2 shows inhibition of growth *in vivo* of NSCLC strain A-549 by M620.

Figure 3 shows inhibition of growth *in vivo* of SCLC strain SHP-77 by B9430.

Figure 4 shows inhibition of growth *in vivo* of SCLC strain SHP-77 by B10238

Figure 5 shows inhibition of growth *in vivo* of SCLC strain SHP-77 by M570, both as the trifluoroacetate salt and as the hydrochloride salt.

30 Figure 6 shows inhibition of growth *in vivo* of SCLC strain SHP-77 by M822.

Figure 7 shows inhibition of growth *in vivo* of SCLC strain SHP-77 by M638.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a range of monomeric, dimeric, trimeric, tetrameric, pentameric and cyclic small peptides and peptide mimics that are effective as anti-cancer agents.

In general, the anti-cancer agents (ACA) are described by the formula:



wherein X is a linker group having 2-5 functional groups or is absent, $n = 1$, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI, as described herein. Other compounds described herein are defined by the Formula VII, as described herein.

X can be any linking group which does not interfere with the inhibitory activity of the monomer-linker or oligomerized product using *bis*-imido-esters, *bis*-maleimidoalkanes such as *bis*-maleimidohexane, dicarboxylic acids, tricarboxylic acids, tetracarboxylic acids and multi carboxylic acids. Alkane groups may be substituted with alkyl, amino, carboxyl, halogen, hydroxy, mercapto or methoxy groups. Aminoalkyl, aromatic or cycloalkyl polycarboxylic acids, heterocyclic polycarboxylic acids, carboxylic anhydrides and polyoxyethylene linkers may also be used. For C-terminal crosslinking, X may be any diamino or polyamino alkane, cycloalkane, aromatic, heterocyclic diamine, polyamine or other substituted chelating agent (for example: diethylenetriaminepentaacetic dianhydride, ethylenediaminetetraacetic dianhydride, etc.). Polyamino-polycarboxylic acids may also be used to make heteromers (such as ethylenediamine-N,N'-diacetic acid, etc.).

The linkage may be at the N-terminal or the C-terminal or at any position of the ACA sequence through side-chain functional groups. The linker may have any chain length.

For dimers, there is a correspondence between linker length and cytotoxicity. Alkyl chains of 8 carbons or more are preferred, with those of 8 to 18 carbons being most preferred. Examples of preferred dimer linkers for the α -amino at the N-terminal or for a basic side-chain


5 group at any position of ACA include ADA, BTAC, DDD, DDS, DTP, EGS, EOPC, HDD, HFG, PFS, SBEC, SUB, SUIM and TDIM. For dimerization through the C-terminal carboxyl or any side-chain carboxyl in ACA, the preferred linkers include DDA, DEA, EDA, EDP and HAD. Any di-functional molecule can be used.

10 For trimers, linkers for basic groups include BTAC, BTC, CHTC, CTAC and TREN-(Suc)₃; for carboxyl groups, TREN. Any tri-functional molecule can be used.

For tetramers, linkers can be BAPTA, CPTA, EDTA, EGTA, ETТА, or any tetra-functional molecule.

For pentamers, the linker can be DTPA or any pentameric functional molecule. Compounds formed by ACA and a linker X may be homo or hetero multimers.

[Formula II] comprises:



20 wherein R, A, B, C, D, E, F, G, H, I, J, and K are selected from the following or may be absent, and wherein K is Arg or an Arg derivative:

| R | A -1 | B 0 | C 1 | D 2 | E 3 | F 4 | G 5 | H 6 | I 7 | J 8 | K 9 |
|------------------------------------|---|------------------------------------|-----------------------------------|-----------------------------------|----------------------------|------------------------------------|-----------------------------------|-----------------------------------|--------------------------------------|--|--|
| Absent or 3,3DP Aaa Ac | Absent or DmK Lys Lys(εF lu) | Absent or Apc Arg DArg | Absent or ApC Arg DmK | Absent Or MeP Nig NMF | Absent or Hyp Pro | Absent or Ava BALa Dpr | Absent or Add Aud CpG | Absent or Arg Gly Pac | Absent or 2Nal DCpG DF5F | Absent or 2Nal 2Nal- NH ₂ | Absent or Arg Arg(H) Arg- CH ₂ O H Arg- NH ₂ Arg(N O ₂) Arg- OMe DArg DArg- NH ₂ DArg(NO ₂) |
| Aca | NiK | DLys | NiK | Pro | | Eac | DDMF | Pac | DIgl | 3,4F2F | |
| BAPg | PzO | DmK | NiO | | | Gly | DMF | Ser | DPFF | 3Pal | |
| Cca | | DniK | PaF | | | | Eac | Thr | DPhe | Ac6c | |
| Cin Dca | | DpaF DPzK | PzO | | | | Igl Lys | | DTic Gly | Aic Ana | |
| Dcg | | DPzO | | | | | Pac | | mABz | Apb | |
| Dhq | | Lys | | | | | Phe | | pABz | Apb | |

Dmac
Dpa

F5bz
F5c

F5pa
Gun

Hxa

Mca
Mcg

Moti
Pcc
Ppa
Pya

Saa
Ste

Tfmc

NiK
PaF


PzO
DArg- Arg-
(NO₂) (NO₂)

| | |
|--------------|--|
| Pac | Atpc |
| PaF(Dc g) | Bip |
| <i>p</i> Amb | Cmp |
| | CpG |
| | DhPhe |
| | Dpr(Fb z) |
| | Dpr(Pa a) |
| | F5F |
| | F5F- NH ₂ |
| | Hphe |
| | Ica |
| | Igl |
| | Igl- NH ₂ |
| | Ileu |
| | Lys(C H ₃) ₃ |
| | Lys(F5 bz) |
| | <i>Mapa</i> |
| | MBC |
| | MFF |
| | Nc6G |
| | Nc7G |
| | NMF |
| | OBS |
| | OBT |
| | OBY |
| | OC2Y |
| | Oic |
| | Oic- NH ₂ |
| | PABz |
| | Pac |
| | PaF(F5 c) |
| | PaF(Fb z) |
| | PaF(M cg) |
| | PaF(Pp a) |
| | PaF(Si n) |
| | <i>p</i> Amb |
| | <i>p</i> APa |
| | PCF |

PdF
PFF
PFF-
NH₂
Phe
PNF
Thi
Tic
Trp
Trx
Tyr

5.

[Formula III] comprises:



wherein R, A, B, C, D, E, and F are selected from the following or may be absent, and wherein F is not Arg or an Arg derivative:

| R | A | B | C | D | E | F |
|-----------------------------|--|------------------|-------------------------|---------------------------|----------------------------|----------------------------|
| | 1 | 2 | 3 | 4 | 5 | 6 |
| Absent or 2,2Dp 3,3Dp | Absent or DArg DArg(NO ₂) | Absent or Arg | Absent or Add Aud | Absent or 2Nal 3Pal | Absent or 1Nal 2Nal | Absent or 2Nal 3Pal |
| Aaa | | | Ava | Arg | 2Nap | ABza |
| Ac | | | Eac | Arg(Tos) | 3Pal | ABza |
| Aca | | | Lys | Atcp | Apa | Ama |
| Boc | | | Pac | D2Nal | Arg | Ampy |
| Chc | | | | DArg | Arg-NH ₂ | Ampz |
| Cin | | | | DArg(Tos) | Asp | Apa |
| Ctim | | | | DF5F | Atc | Api |
| Dca | | | | DIgl | Atcp | Aptp |
| Dcg | | | | DPFF | Bip | Aqd |
| Dhq | | | | Eac | BtA | Aqu |
| Dmac | | | | F5F | Cys(Meb) | Arg(H) |
| Dns | | | | Gly | Cys(SO ₃ H) | Arg- CH ₂ OH |
| Dpa | | | | His | D2Nal | Arg-NH ₂ |
| F5c | | | | Igl | DArg | Arg-OMe |
| F5pa | | | | mABz | DArg-NH ₂ | Asp |
| F5po | | | | OC2Y | F5F | Asp(Aqu) |
| Gbc | | | | Pac | Glu | Atcp |
| Gun | | | | PFF | Gly | Atmp |
| Hxa | | | | | Igl | AtmpO |
| Mcg | | | | | Inp | Atpm |
| Mse | | | | | Iqa | Cyh |

| | |
|-----------------------|-------------------------------|
| <i>m</i> ABz | Dmab |
| MC2Y | Dmm |
| N-Dmb- | Dmp |
| Tyr(Bz)- | |
| OMe | |
| OC2Y | Dpea |
| OCiY | Dpma |
| Oic | Dpr(Dcg-2- |
| | Nap) |
| <i>p</i> ABz | Ecap |
| PaF(Mes) | F5F-NH ₂ |
| PFF | GaP |
| Tic | <i>m</i> A ₂ Bz |
| <i>i</i> Leu | <i>m</i> A ₂ Bz(Dc |
| | g) |
| Trp | <i>m</i> A ₂ Bz(Gu |
| | n) |
| Try | <i>m</i> ABz |
| Try(Bzl) | Mapp |
| Tyr | Matp |
| Arg(NO ₂) | MatpO |
| | <i>p</i> ABz |
| | PaF |
| | PaF(Dcg) |
| | PaF(Mcg) |
| | PaF-NH ₂ |
| | PFF-NH ₂ |
| | PgF |
| | PzO |
| | Sud |
| | Thm |
| | Thm |
| | Tpac |
| | Tpac |
| | Tyr(Bz)O |
| | Me |

| | |
|-----------------------|-------------------------------------|
| <i>p</i> ABz | Ecap |
| PaF(Mes) | F5F-NH ₂ |
| PFF | GaP |
| Tic | <i>m</i> A ₂ Bz |
| <i>i</i> Leu | <i>m</i> A ₂ Bz(Dc g) |
| Trp | <i>m</i> A ₂ Bz(Gu n) |
| Try | <i>m</i> ABz |
| Try(Bzl) | Mapp |
| Tyr | Matp |
| Arg(NO ₂) | MatpO |
| | <i>p</i> ABz |
| | PaF |
| | PaF(Dcg) |
| | PaF(Mcg) |
| | PaF-NH ₂ |
| | PFF-NH ₂ |
| | PgF |
| | PzO |
| | Sud |
| | Thm |
| | Thm |
| | Tpac |
| | Tpac |
| | Tyr(Bz)O |
| | Me |


[Formula IV] comprises:

$$A^0-B^1-C^2-D^3-E^4-F^5-G^6-H^7-I^8-J^9-K^{10}-L^{11}$$

10 wherein A, B, C, D, E, F, G, H, I, J, K and L are selected from the following or may be absent:

| A | B | C | D | E | F | G | H | I | J | K | L |
|----------------------|---------------------|---------------------|---------------------|---------------------|----------------------|---------------------|----------------------|---------------------|----------------------|------------------------|--|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| Absent or DArg | Absent or Arg | Absent or Pro | Absent or Lys | Absent or Pro | Absent or DTrp | Absent or Gln | Absent or DTrp | Absent or Phe | Absent or DTrp | Absent or Leu(r) | Absent or Leu- NH ₂ Leu |
| DArg | | | | DNMF | | | | | | | |


[Formula V] comprises:




10 wherein X, A, B, C, D, E, F, G, H, I, J, and K are selected from the following or may be absent:

| X | A | B | C | D | E | F | G | H | I | J | K |
|--|---|--|-----------------------------------|---------------------|---------------------|---------------------|--|------------------------------------|--|--|--|
| | -1 | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| Absent or α -Aca 3,3Dp | Absent or Ava BALa DmK Glt Lys Suc | Absent or DArg DNik DPaF DPzK DPzO | Absent or Arg NiK PzO | Absent or Pro | Absent or Hyp | Absent or Gly | Absent or Add Aud Ava BALa DNMF Eac Igl Thi | Absent or DArg Ser Thr | Absent or DDab DDpr DF5F DIgl DLys DOm DPaF Nig Pac Phe | Absent or DTrp F5F Lys Nc7G Oic PaF PFF Phe | Absent or Arg Leu NiK PaF 3Pal |

[Formula V] also comprises:




[Formula V] also comprises:




20 wherein the cyclization is via a side chain functional group other than the C-terminal residue and the residues are as described in the immediately preceding table.

[Formula VI] comprises the following cyclic peptides:



ACA can also be those compounds in Table 4.

[Formula VII] comprises:



10

wherein [ACA] is defined by Formula I or the compounds in Table 4.

15

The *in vivo* inhibitory effects of antagonists may be studied using tumor-bearing nude mice. A tumor model employing nude mice orthotopically implanted with human lung cancer cells wherein the ACA is delivered by intratracheal instillation and aerosol inhalation may be used to evaluate the efficacy and feasibility of these antagonists as a means of treating human lung cancers. Control animals without tumor implantation may also be used to study the general side effects or cytotoxicity of the compounds. It is believed that aerosolized delivery or intratracheal instillation of the agents can produce effective dose accumulation in the area of lesion and reduce the overall systemic toxicity of the compounds in the animals more than when the compound is delivered by systemic administration.

20

25

The compounds may be administered topically, or by injection or infusion or as an oral suspension in an appropriate vehicle or as tablets, pills, capsules, caplets or the like, or preferably via intratracheal instillation or aerosol inhalation. The dosage and manner of administration will be defined by the application of the ACA and can be determined by routine methods of clinical testing to find the optimum dose. These doses are expected to be in the range of 0.001 mg/Kg to 100mg/Kg of active compound.

30

The compounds are composed of amino acids which may form salts due to their acidic or basic nature, and any pharmacologically acceptable salt derived from the compounds described in this invention such as hydrochlorides, acetates, phosphates, maleates, citrates, benzoates, salicylates, succinates, ascorbates and the like, including HCl, trifluoroacetic acid (TFA), and HOAc, are considered an extension of this invention. A common tactic in medicinal chemistry is to modify known drug substances which are peptide based to form esters or amides which exhibit greater bioavailability. Prodrugs derived from the compounds disclosed here are

5 therefore considered an obvious extension of this invention. Methods for designing and preparing prodrugs are described in detail in the medicinal chemical literature.

Structures and biological activities of peptides and peptide mimics related to bradykinin (BKR) are given in Table 1. Structures and biological activities of compounds not related to bradykinin (BKU) are given in Table 2. Structures and biological activities of cyclic peptides are
10 given in Table 3. Structures of previously described known peptides which we have found to be active against cancers *in vivo* are included in Table 4. Actions of selected compounds on prostate cancer cell lines are given in Table 5. Abbreviations used are as defined in Table 6.

EXAMPLES

In general, Anti-bradykinin activity was determined by the classical guinea pig ileum assay and on Chinese hamster ovary (CHO) cells expressing cloned human bradykinin B2 receptors. Anti-tumor activity was determined on cultured human cancer cell lines using the standard tetrazolium (MTT) assay. No correlation between anti-bradykinin and cytolytic activity was found among the compounds, indicating that cells are not killed due to inhibition of an essential bradykinin function. Potent compounds were found to stimulate apoptosis in SCLC cells, probably by abnormal activation of the intracellular MEKK pathway.

EXAMPLE I – Synthesis of peptides

Peptides were synthesized using standard solid phase synthesis methods, well known in
25 the art (Stewart and Young, *Solid Phase Peptide Synthesis*, Pierce Chemical Co., Rockford, IL, 1984) and were purified by HPLC and were characterized by amino acid analysis (AAA), thin layer chromatography (TLC) and laser desorption mass spectrometry (LDMS). Peptide amides were synthesized on methylbenzhydrylamine (MBHA) resin, which yields amides directly. Peptide methyl esters (OMe) were synthesized by reaction of peptides with 2,2-
30 dimethoxypropane (Rachele, *J. Org. Chem.* 28: 2898, 1963). Cyclic peptides were prepared on resin or in solution with PyAOP and HOAt .

EXAMPLE II – Synthesis of non-peptides

Non-peptides were synthesized by standard organic chemistry procedures well known in the art. Compounds were purified by HPLC and were characterized by analytical HPLC, TLC, and LDMS.

EXAMPLE III – Synthesis of DDD and SUB dimers

Synthesis on resin: Neutralized peptide-resin (0.05mmole) was treated with 0.15 mmole diisopropylethyl amine (DIEA) and 0.026 mmole dodecanedioyl dichloride or suberoyl dichloride in 2.5 mL dichloromethane (DCM). The suspension was mixed for 5 h, washed with DCM and ethanol and dried. The peptide dimer was cleaved from the resin with HF, and the peptide was extracted and purified

Synthesis in solution: Carboxyl-derivatized amino acids or dipeptides were dissolved in dimethyl formamide (DMF) and treated with 10 equivalents of DIEA and 0.55 equivalent of dodecanedioyl dichloride or suberoyl dichloride overnight. The DMF was evaporated *in vacuo* and the resulting dimer was purified by HPLC.

EXAMPLE IV – Synthesis of EGS, DTP, SBEC and SUB dimers in solution

Dimerization in solution proceeded by reacting 1 equivalent of peptide monomer trifluoroacetate, an excess of DIEA and 0.55 equivalent of cross-linking reagent overnight in DMF. The cross-linking agents were purchased from Pierce (EGS dimer, ethylene glycol *bis*-(succinimidylsuccinate); DTP dimer, dithio*bis* (succinimidyl propionate); SBEC dimer, *bis*[(2(succinimidooxycarbonyloxy)ethyl)sulfone; SUB dimer, disuccinimidyl suberate).

5 **EXAMPLE V – Synthesis of Boc-N-cycloheptylglycine (Nc7G)**

N-Cycloheptylglycine was synthesized by reductive amination of cycloheptanone with glycine methyl ester following the procedure described in Gera *et al.*, *Immunopharmacology*. 33:174-177 (1996). The crude product was converted to the N-Boc derivative (mp, 89-90 °C).

10 **EXAMPLE VI – Synthesis of TDIM dimers**

Dimethyl tetradecyldiimidate was synthesized from tetradecanedinitrile by the method of De Abreu *et al.* (*Eur. J. Biochem.* 97: 379- 387, 1979. One equivalent of peptide TFA salt or other molecule having a free amino group was dissolved in DMF and stirred with 10 equivalents of DIEA and 0.7 equivalent of dimethyl tetradecyldiimidate dihydrochloride overnight at room temperature. DMF was evaporated *in vacuo* and the dimer was purified. SUIM dimers were prepared similarly, using dimethyl suberimidate.

EXAMPLE VII – Synthesis of B10238: F5C-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg (F5c-B9430)

B10238 was made by standard solid phase synthesis procedures, or by the acylation of B9430 with 2,3,4,5,6-pentafluorocinnamic acid in DMF, using BOP coupling in presence of excess DIEA. The product was purified by HPLC.

EXAMPLE VIII – Synthesis of M822: DDD-(DArg-F5F-Arg)₂

Following standard solid phase synthesis procedures, Boc-Arg(Tos) Merrifield synthesis resin was coupled with Boc-F5F, followed by coupling with Boc-DArg(Tos), using HATU as coupling agent. The peptide-resin was deprotected with TFA-DCM and neutralized with TEA. The peptide-resin was then treated with 0.55 equivalent of dodecanedioyl dichloride and 5 equivalents of DIEA in DCM overnight at room temperature. After washing and drying, the resin was cleaved with anhydrous HF, using standard conditions. The peptide was extracted from the resin with 90% acetic acid and purified by preparative HPLC.

EXAMPLE IX – Synthesis of M570 Hydrochloride: F5c-OC2Y-Atmp.HCl

4-Amino-2,2,6,6-tetramethylpiperidine (Aldrich) was coupled with Boc-(O-2,6-dichlorobenzyl)-tyrosine, using BOP in DMF solution. The Boc protecting group was removed by TFA and the product coupled with 2,3,4,5,6-pentafluorocinnamic acid in DMF, using BOP in the presence of excess DIEA at room temperature for 3 h. The DMF was removed *in vacuo*, the product was extracted into ethyl acetate and the solvent was evaporated. The residue was treated with 0.1 - 1.0 N HCl or 20% ethanolic HCl. The solvent was removed by evaporation *in vacuo* at room temperature. The residue was lyophilized from water-dioxane or crystallized from ethanol-ether.

EXAMPLE X – Synthesis of M630: Dmac-OC2Y-Matp.TFA

4-Methylamino-2,2,6,6-tetramethylpiperidine (Matp) was synthesized from 2,2,6,6-tetramethyl-4-piperidone (Aldrich) and methylamine by reductive amination with NaCNBH₃. The Matp was coupled with Boc-(O-2,6-dichlorobenzyl)-tyrosine, using BOP in DMF solution. The Boc protecting group was removed by TFA and the product was coupled with 4-(dimethylamino)cinnamic acid in DMF, using BOP in the presence of excess DIEA at room temperature for 3 h. The DMF was removed *in vacuo*. The product was extracted into ethyl acetate and the solvent was evaporated *in vacuo*. The crude product was purified by HPLC, giving the TFA salt. The Dmac-OCTY-Matp.TFA salt can be converted to its HCL salt as in Example IX above.

EXAMPLE XI – Synthesis of M638: DDD-(DArg-Igl-Arg-Matp)₂

In sequence, Boc-Arg(Tos), Boc-Igl and Boc-DArg(Tos) were coupled to 4-methylamino-2,2,6,6-tetramethylpiperidine (Matp), using BOP as coupling agent in DMF in the presence of excess DIEA at room temperature for 3-5 h. After removal of DMF *in vacuo*, the product was extracted into ethyl acetate. After evaporation of the solvent, the residue was treated with TFA-

5 DCM to remove the Boc group. TFA was removed *in vacuo*. The DArg(Tos)-Igl-Arg(Tos)-
Matp.TFA was treated with dodecanedioyl dichloride (0.55 equiv) and DIEA (5 equiv) in DCM
for 5 h. The protecting groups were cleaved by HF and the lyophilized product was purified by
HPLC. The M638.TFA salt was converted to its HCl salt, using 0.1 - 1.0 N HCl or 20%
ethanolic HCl as in Example IX above.

10

EXAMPLE XII – Synthesis of M590: Atmp-Igl-Pac- α -Sbl-Lys-B9430

In sequence, Boc-Igl, Boc-Pac and mono-methyl sebacate were coupled to 4-amino-
2,2,6,6-tetramethylpiperidine (Atmp), using BOP coupling agent in DMF in presence of excess
DIEA at room temperature for 3-5 h. DMF was removed *in vacuo* and the product was extracted
into ethyl acetate. After evaporation of the solvent, the methyl ester was hydrolyzed in methanol
by 1N NaOH. The crude product (0.025 mmol Atmp-Igl-Pac-Sbl) was coupled to the peptide
resin (0.02 mmol Lys(2-ClZ)-DArg(Tos)-Arg(Tos)-Pro-Hyp-Gly-Igl-Ser(Bzl)-DIgl-Oic-
Arg(Tos)-Merrifield resin) using BOP/DIEA activation in DMF. The heterodimer peptide was
cleaved from the resin with HF, using standard conditions. The peptide was extracted from the
resin with acetic acid and purified by preparative HPLC.

EXAMPLE XIII – Synthesis of M872: c[DArg-Arg-Eac-Ser-DF5F-Oic-Arg]

Following standard solid phase synthesis procedures, Boc-DArg(Tos) was coupled to
Boc-Arg(Tos) Merrifield synthesis resin, followed in sequence by Boc-Arg(Tos), Boc-Oic, Boc-
DF5F, Boc-Ser(Bzl), and Boc-Eac, using HATU as coupling agent. After deprotection with
TFA-DCM, the resin was cleaved with anhydrous HF using standard conditions. The peptide
was extracted from the resin with 0.1% TFA-H₂O/dioxane and lyophilized. The peptide
trifluoroacetate was cyclized with three equivalents of PyAOP and HOAt and 20 equivalents of
DIEA in DMF at a concentration of 10⁻³ M. After removal of the solvent under reduced
pressure, the product was lyophilized from dioxane-H₂O and purified by HPLC.

5 **EXAMPLE XIV – Synthesis of M678: (Dns-DArg-Igl-Arg)₂-DDA**

In sequence, Boc-Arg(Tos), Boc-Igl and Boc-DArg(Tos) (2 equivalents) were coupled to 1,10-decanediamine using BOP as a coupling agent in DMF in presence of excess DIEA at room temperature for 3-5 h. DMF was removed *in vacuo* and the product was extracted into ethyl acetate. The solvent was evaporated *in vacuo* and the residue was treated with TFA/DCM to
10 remove the Boc group. TFA was removed *in vacuo*, and the product was treated with dansyl chloride (2 equivalents) and an excess of DIEA in DCM for 5 h. The Tos groups were cleaved by HF and the crude product was purified by HPLC.

EXAMPLE XV – Synthesis of M290: BTAC-(2-Nal-Atmp)₃

The benzene-1,3,5-*tris*-carbamido- ϵ -caproic acid linker was made from 1,3,5-benzenetricarboxylic acid and N-Boc- ϵ -caproic acid methyl ester, using the BOP coupling method. The methyl ester was hydrolyzed in methanol by 1N NaOH. The product (1 equivalent BTAC) was coupled to 2-Nal-Atmp (3 equivalents) in DMF, using HATU as coupling agent. The solvent was removed *in vacuo*, and the residue was purified by HPLC. The BTAC-(2-Nal-Atmp)₂-OH was also isolated as a by-product.

EXAMPLE XVI – Synthesis of M1040: EDTA-(OC2Y-ATMP)₄

Boc-(O-2,6-dichlorobenzyl)-tyrosine was coupled with 4-amino-2,2,6,6-tetramethylpiperidine overnight in DMF, using BOP as coupling agent in the presence of DIEA.
25 After removal of DMF *in vacuo*, the residue was extracted into ethyl acetate and treated with TFA/DCM to cleave the Boc group. The TFA/DCM was evaporated *in vacuo* and the product (OCTY-ATMP) was lyophilized from dioxane/water. Ethylenediaminetetraacetic acid (0.25 equivalent EDTA) was coupled with OC2Y-ATMP trifluoroacetate (1 equivalent) in DMF, using BOP as coupling agent in the presence of DIEA. The solvent was removed *in vacuo* and the
30 residue was purified by HPLC.

5 **EXAMPLE XVII - Assay of anti-bradykinin activity on guinea pig ileum**

Male Hartley guinea pigs that had been deprived of food overnight were sacrificed, and sections of terminal ileum, 25 mm in length, were dissected, attached to tissue holders and immersed in 10 ml tissue baths containing Krebs' solution bubbled with 95%O₂/5%CO₂. Tissues were placed under 1 g tension and incubated for 1 h equilibration. Concentration-effect curves were constructed to bradykinin in the absence and presence of new compounds. Bradykinin showed pD₂ = 7.4, and antagonist B9430 showed pA₂ = 7.9.

EXAMPLE XVIII - Assay of anti-bradykinin activity on cloned human B2 receptors

Chinese hamster ovary cells containing cloned and expressed human bradykinin B2 receptors were grown in cell cups of the Cytosensor microphysiometer in Ham's F-12 medium supplemented with sodium pyruvate and 10% FBS (Gibco 11765-054). For assay the cells were transferred to Ham's F-12 without bicarbonate or serum (Gibco 21700-075) and placed in the Cytosensor. Concentration-response curves were constructed to bradykinin in the presence or absence of new compounds. Bradykinin showed pD₂ = 11, and antagonist B9430 showed pA₂ = 10.5

EXAMPLE XIX - Colorimetric tetrazolium assay for cell survival

Cell growth and survival were measured by a rapid colorimetric assay based on the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Mosmann, *J. Immunol. Methods* 65: 55-63, 1983, with minor modifications). Briefly, 1,000 normal lung fibroblasts or normal epithelial BEAS-2B cells, 1,000 or 5,000 viable non-SCLC cells or 10,000 viable SCLC cells were plated in 100 µL of growth medium in 96-well flat-bottomed microtiter plates. Cells were incubated overnight to allow recovery. Compounds to be tested were added to the cells in triplicate in a range of concentrations and the cells were incubated at 37°C, 5% CO₂, with 100% humidity. Control cells were treated in the same way without antagonists. All wells had a final volume of 200 µL. Plates were incubated for 4 days, allowing

5 sufficient time for cell replication and compound-induced cell death to occur. On day 5, 25 μ L of
a 2 mg/mL solution of MTT (Sigma) dissolved in RMPI-1640 was added to each well. The plate
was incubated for 4 h at 37°C. The supernate was removed and the blue formazan complex was
dissolved by adding 100 μ L of 0.02 N HCl in 75% isopropanol to all wells. Absorbance was
immediately determined using a scanning multiwell plate reader. B9870 caused 50% cell death at a
10 concentration of 0.15 μ M under these conditions.

EXAMPLE XX - Measurement of apoptosis in cultured cells

Apoptosis, also known as programmed cell death, is the phenomenon by which a cell dies
following a series of gene-mediated events, in response to a wide range of intracellular and
extracellular agents. Apoptosis, a counterpart of mitosis, plays an important role in the
development and homeostasis of many organisms and tissues. It serves to regulate cell numbers,
to shape developing organisms and as a defense against potentially harmful agents. Apoptosis is
not the only mode of cell death. Necrosis is a type of cell death which is nonspecific and
frequently occurs when cells are exposed to high doses of toxic agents. Such exposure usually
results in the loss of ionic homeostasis. Unlike apoptosis, necrosis does not seem to be
genetically influenced.

Apoptotic and necrotic cells have different appearances which allow them to be
distinguished microscopically. Necrotic cells and their mitochondria swell, the cell membrane
eventually ruptures, and internal organelles become distended. As a result of the membrane
25 rupture, inflammation occurs in the surrounding tissue. In contrast, the nuclei of apoptotic cells
become fragmented into several smaller nuclear bodies, which are quickly recognized by
phagocytes and engulfed, and no inflammatory response occurs. Therefore, it is useful to
develop chemotherapeutics which induce apoptosis, rather than necrosis, in order to avoid
inflammation and the toxic agents which are often released from necrotic tumor cells.

30 We have used differential fluorescent dye uptake and cellular morphology to distinguish
viable and dead cells with apoptotic and/or necrotic morphologies. We have used Rhodamine 123

5 to stain active mitochondria in viable cells, Hoechst 33324 to stain DNA in both viable and dead
cells, and Propidium Iodide to stain DNA in dead cells. These cell subpopulations may be
distinguished by the different manners in which they take up the fluorescent probes. The dead
apoptotic and necrotic subpopulation, which has lost its membrane potential and organelle
function, takes up Propidium Iodide and Hoechst 33324. Since the cells in this subpopulation
10 are dead, the mitochondria are not active and thus there is little or no uptake of Rhodamine 123.
Under the fluorescence microscope with a DAPI filter, nuclei in these cells appear pinkish in
color due to the mixing of both Propidium Iodide and Hoechst 33324 dyes. Necrotic cells have
intact nuclei while apoptotic cells have fragmented multi-nucleated bodies. In contrast, the viable
apoptotic subpopulation has an intact membrane but inactive mitochondria. As a result, the
fragmented multi-nucleated bodies (a hallmark of apoptotic cells) in these cells take up only
Hoechst 33324, which gives them a blue appearance under the fluorescence microscope, but are
unable to take up Propidium Iodide or Rhodamine 123. The subpopulation of viable cells has
both intact cell membranes and active mitochondria. These cells take up both Hoechst 3324 and
Rhodamine 123. Microscopically these cells appear to have single normal blue nuclei when
examined with a DAPI filter and bright green mitochondria when examined with a FITC filter.

EXAMPLE XXI – Inhibition of tumor growth *in vivo* in nude mice

Representative peptide and non-peptide compounds having high *in vitro* cytotoxic
activity were tested against implanted tumors *in vivo*. Athymic nude mice were implanted
25 subcutaneously with either single cell suspensions (2 million SCLC cells or 1 million NSCLC
cells) or with small fragments (3 x 3 mm) of tumors minced from previously grown nude mouse
heterotransplants. On the seventh day after tumor implantation groups of 5 mice bearing
implants were injected intraperitoneally daily with the compounds being tested at 1, 5, or 10
mg/kg/day; control animals were injected with an equal volume of isotonic saline. Tumor size was
30 measured with a caliper three times per week. Tumor volume was calculated by the formula:

$$\text{Volume (cc)} = \pi \times (\text{length}) \times (\text{width})^2 / 6$$

5 Results of representative *in vivo* tests are given in Figs. 1-8. For comparison, bradykinin antagonist peptide dimers B9870 and B10054 caused marked inhibition of growth of the SCLC line SHP-77 at a dose of 5 mg/kg/day.

EXAMPLE XXII - Data

10 Examples of peptides and peptide mimics related to the C-terminal part of bradykinin antagonist peptides and their biological activities on cancer cells and bradykinin responses are given in Table 1.

Many compounds not directly related to the structure of bradykinin were synthesized and tested for anti-tumor and anti-bradykinin activity. These are listed in Table 2.

Cyclic peptides related to bradykinin and bradykinin mimics are reported in Table 3, along with their biological activity on cancer cells and anti-bradykinin activity.

Structures of previously described known peptides which have been found to be active against cancers *in vivo* are included in Table 4.

Cytotoxic activity *in vitro* of compounds M570 and M590 against various standard strains of prostate cancer is reported in Table 5.

Standard abbreviations were used for natural amino acids. For non-natural amino acids, derivatizing groups and other chemicals, the abbreviations listed in Table 6 are used.

5 Table 1. ACTIVITIES OF PEPTIDES RELATED TO BRADYKININ STRUCTURE

| NUMBER | STRUCTURE | MTT ^a | GPI ^b | HUMAN ^c |
|----------------------|---|------------------|------------------|--------------------|
| BK ^d | Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg | | | |
| B9430 ^d | DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | 120 | 8.2 | |
| B9870-2 ^d | SUIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg) | 0.15 | 8.4 | |
| B8838 | DArg-Arg-Pro-Hyp-Gly-CpG-Ser-DCpG-CpG-Arg | -- | 7.0 | |
| B8840 | DArg-Arg-Pro-Hyp-Gly-Phe-Ser-DCpG-CpG-Arg | -- | 6.8 | |
| B8858 | DArg-Arg-Pro-Hyp-Gly-Thi-Ser-CpG-DCpG-DArg | -- | 5.2 | |
| B8994 | DArg-Arg-Pro-MeP-Gly-CpG-Ser-DCpG-CpG-Arg | -- | -- | |
| B9074 | Dhq-DArg-Arg-Pro-Hyp-Gly-CpG-Ser-DCpG-CpG-Arg | -- | 6.3 | |
| B9126 | Aaa-DArg-Arg-Pro-Hyp-Gly-(D,L)DMF-Ser-DTic-Oic-Arg | -- | 6.4 | |
| B9126-2 | Aaa-DArg-Arg-Pro-Hyp-Gly-(D,L)DMF-Ser-DTic-Oic-Arg | -- | 7.3 | |
| B9224-2 | Aca-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-(D,L)Igl-Oic-Arg | -- | 8.4 | |
| B9882 | α -Sub-Lys(eFlu)-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | -- | -- | |
| | ^L DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | -- | -- | |
| B9914 | Oic-Arg | -- | Wk | |
| B9916 | DIgl-Oic-Arg | -- | Wk | |
| B9490 | Dcg-Digl-Oic-Arg | >60 | Wk | |
| B9918 | Ser-Digl-Oic-Arg | -- | -- | |
| B9920 | Igl-Ser-DIgl-Oic-Arg | -- | -- | |
| B9922 | Gly-Igl-Ser-DIgl-Oic-Arg | -- | Wk | |
| B9924 | Hyp-Gly-Igl-Ser-Digl-Oic-Arg | -- | -- | |
| B9926 | Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | -- | -- | |
| B9950 | α -Lys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | 8 | -- | |
| | Sub-Arg-DNMF-DTrp-Phe-DTrp-Leu | | | |
| B9956 | α -DDD-(Lys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg) ₂ | -- | -- | |
| B9960 | DArg-Arg-Nig-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | -- | 7.7 | |
| B9966 | DArg-Arg-NMF-Hyp-Gly-Thi-Ser-DIgl-Oic-Arg | -- | 6.9 | |
| B10010 | DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Nc7G-Arg | -- | 7.7 | |
| B10014 | DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nc6G-Arg | -- | 7.6 | |
| B10054 | DDD-(Lys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg) ₂ | 0.3 | 7.1 | |
| B10062 | DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg-NH ₂ | Inact | 7.1 | |
| B10082 | SUIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg-NH ₂) ₂ | 0.7 | 7.2 | |
| B10084 | BAPG-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | >20 | 8.1 | |
| B10088 | DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg-Eac-Eac-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | 4 | 7.1 | |

| | | | | |
|----------|--|-----|-----|----|
| B10092 | (Gun) ₂ -BApG-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | >20 | 8.7 | |
| B10098 | (DArg-Arg-Pro-Hyp) ₂ -Dpr-Igl-Ser-DIgl-Oic-Arg | 20 | 5.3 | |
| B10100-2 | TDIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg) ₂ | 1 | 8.0 | |
| B10100-1 | Moti-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | 4 | 7.8 | |
| B10104-2 | TDIM-(DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DIgl-Oic-Arg) ₂ | 4 | 8.0 | |
| B10104-3 | Moti-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DIgl-Oic-Arg | 20 | 8.1 | |
| B10160 | Leu-DTrp-Phe-DTrp-DNMF-Eac ₂ -DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | 10 | 6.3 | |
| B10162 | Leu-Leu-DTrp-Phe-DTrp-DNMF-Eac ₂ -DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | 7 | 6.3 | |
| B10198-1 | DDD-(Eac-Arg-DIgl-Oic-Arg) ₂ | -- | 5.7 | |
| B10198-2 | DDD-(Eac-Arg-DIgl-Oic-Arg) ₂ | 15 | -- | |
| B10200 | DDD-(Eac-Eac-Arg-DIgl-Oic-Arg) ₂ | 16 | 5.8 | |
| B10238 | F5c-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | 150 | 8.1 | |
| B10252 | EGS-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg) ₂ | 25 | 8.3 | |
| B10282 | Arg-Pro-Pro-Gly-Phe-Thr-DTic-Oic-Arg | -- | 7.3 | |
| B10284 | Arg-Pro-Pro-Gly-Phe-Thr-DTic-Oic-NH ₂ | -- | 7.7 | |
| B10382 | DArg-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg | -- | -- | |
| B10384 | DNiK-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg | -- | -- | |
| B10386 | DDD-(DmK-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg) ₂ | -- | -- | |
| B10388 | DNiK-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg | -- | -- | |
| B10390 | DNiK-PzO-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg | -- | -- | |
| B10392 | DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-PFF-Arg | -- | -- | |
| B10394 | F5c-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-PFF-Arg | -- | -- | |
| B10396 | F5c-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-PFF-Arg | -- | -- | |
| M2 | Dcg-D-2-Nal-Arg | -- | -- | |
| M10 | Dcg-2Nal-Arg | -- | 4.8 | -- |
| M20 | Gun-2-Nal-Arg | -- | 4.6 | |
| M42 | Gun-Eac-DIgl-Oic-Arg | -- | 5.0 | |
| M68 | Dcg-BtA-Arg | -- | 4.9 | |
| M70 | Dcg-Igl-Arg | -- | 4.8 | |
| M78 | Dcg-Apa-Arg | -- | 5.6 | |
| M84 | Dcg-Ile-Arg | -- | 5.1 | |
| M86 | Dcg-Ac6c-Arg | -- | 5.0 | |
| M88 | Gun-Ica-Arg | -- | 4.7 | |
| M94 | Dcg-Aic-Arg | -- | Wk | |
| M96 | Dcg-(D,L)Atc-Arg | -- | 4.7 | |
| M118-1 | Ac-PaF(Mcg)-Arg | -- | 4.9 | |
| M118-3 | Ac-PdF-Arg | -- | 5.4 | |
| M124 | Dcg-Gly-Cmp-Arg | -- | 4.7 | |
| M128 | Dcg-Gly-Oic-Arg | -- | Wk | |
| M130 | Dcg-F5F-Arg | 20 | 4.8 | |
| M132 | F5bz-F5F-Arg | 60 | Wk | |
| M134 | Dcg-Trx-Arg | -- | 4.9 | |

| | | | | |
|--------|--|-------|-------|-------|
| M142 | Ac-PaF(Sin)-Arg | -- | Wk | |
| M146-1 | Ac-PaF(Mcg)- <i>p</i> -ABz-Arg | -- | Inact | |
| M146-2 | Ac-PaF(Dcg)- <i>p</i> -ABz-Arg | -- | 4.9 | |
| M148 | F5c- <i>p</i> -ABz-Arg | -- | 5.1 | |
| M160 | Ste-2-Nal-Arg | -- | Wk | |
| M176 | F5c- <i>p</i> ABz-2Nal-Arg | Inact | 5.4 | -- |
| M196 | F5c-Gly- <i>m</i> ABz-2Nal-Arg | Inact | 5.1 | -- |
| M198 | Ac-Pac-Gly- <i>m</i> -Abz-2-Nal-Arg | -- | 5.1 | |
| M200-1 | Mcg-Pac-Gly- <i>m</i> -ABz-2-Nal-Arg | -- | Inact | |
| M200-2 | Dcg-Pac-Gly- <i>m</i> -ABz-2-Nal-Arg | -- | 4.9 | |
| M216 | F5c- <i>p</i> -APa-Arg | >180 | -- | |
| M226 | DDD-(Arg-DIgl-Oic-Arg) ₂ | 35 | 5.7 | Inact |
| M232-1 | Dcg-Atpc-Arg | -- | 4.7 | |
| M232-3 | Dcg-2-Nal-Atpc-Arg | -- | 5.1 | |
| M346 | Dcg- <i>p</i> -Amb-Arg | -- | 4.6 | |
| M348 | F5c- <i>p</i> -Amb-Arg | -- | 4.7 | |
| M352 | F5c- <i>p</i> -Amb-APa-Arg | -- | 4.7 | |
| M370 | F5c-Arg | -- | 4.8 | |
| M372 | F5c-APb-Arg | -- | 4.6 | |
| M374 | Tfmc-Arg | -- | 4.6 | |
| M380 | F5c-Tyr-Arg | -- | Inact | |
| M382 | F5c-Tic-Arg | -- | 4.7 | |
| M388 | F5c-Lys{(CH ₃) ₃ }-Arg | -- | 4.9 | |
| M392 | F5c-Ana-Arg | -- | 4.5 | |
| M394 | F5c-Bip-Arg | -- | 4.7 | |
| M398 | F5c-Pac-Arg | -- | Inact | |
| M400 | DDD-(<i>p</i> ABz-2Nal-Arg) ₂ | 22 | 5.1 | 11.5 |
| M406 | Arg-Eac-DIgl-Ana-Arg | -- | Inact | |
| M410 | F5c-Phe-Arg | -- | 5.4 | |
| M412 | F5c- <i>m</i> -APa-Arg | -- | 5.8 | |
| M416 | F5c-3-Pal-Arg | -- | Wk | |
| M420 | F5c-hPhe-Arg | 60 | 7.0 | 10.9 |
| M424 | F5c-Thi-Arg | -- | 4.6 | |
| M426 | F5c-Trp-Arg | -- | Inact | |
| M442 | F5c-Oic-Arg | -- | -- | |
| M446 | F5c-2Nal-Arg | 60 | 4.7 | 9 |
| M450 | F5c-2Nal-Arg-NH ₂ | 26 | 4.9 | Inact |
| M484 | DDD-(Pac-2Nal-Arg) ₂ | 25 | Inact | Inact |
| M494 | DDD-(Lys-Pac-Gly- <i>m</i> ABz-2Nal-NH ₂) ₂ | 33 | 5.1 | Inact |
| M498 | DDD-(Pac-2Nal-Arg-NH ₂) ₂ | 24 | 4.9 | Inact |
| M500 | DDD-(<i>p</i> ABz-2Nal-Arg-NH ₂) ₂ | 40 | 0 | 11.4 |
| M504 | DDD-(Pac-2Nal-DArg-NH ₂) ₂ | 11 | 5.4 | Wk |
| M508 | DDD-(DArg-2Nal-Arg) ₂ | 23 | Inact | -- |
| M510 | DDD-(DArg-2Nal-Arg-NH ₂) ₂ | 8 | Inact | 11 |
| M512 | F5c-OC2Y-Arg | 70 | 5.7 | 11 |
| M516 | DDD-(DArg-Arg-Aud-Pac-2Nal-Arg) ₂ | 1.4 | 0 | Ag |
| M518 | DDD-(DArg-OC2Y-Arg) ₂ | 15 | Wk | 10 |
| M520 | F5c-OBS-Arg | Inact | 6.1 | 7 |
| M528 | F5c-MBC-Arg | Inact | Inact | |
| M540 | Pya-hPhe-Arg | >100 | Wk | |
| M542 | Dca-hPhe-Arg | 80 | Wk | |

| | | | | |
|--------|--|-------|-------|-------|
| M550 | F5c-OBT-Arg | 80 | Inact | Ag |
| M552 | DDD-(p-ABz-hPhe-Arg) ₂ | Inact | Inact | |
| M554 | DDD-(DArg-hPhe-Arg) ₂ | -- | 5.1 | |
| M558 | Dcg-hPhe-Arg | 100 | Wk | |
| M560 | DDD-(DArg-hPhe-Arg-NH ₂) ₂ | 50 | Wk | |
| M564 | DDD-(DArg-OBS-Arg) ₂ | -- | Wk | |
| M590 | Atmp-Igl-Pac-α-Sbl-Lys-B9430 | 4.5 | 7.5 | Inact |
| M598 | DDD-(Arg-DIgl-Oic-Arg-OMe) ₂ | 13 | -- | 10 |
| M600 | α-DDD-(Lys-B9430-OMe) ₂ | 1.2 | 6.4 | Ag |
| M608 | DDD-(Eac-Arg-DIgl-Oic-Arg-OMe) ₂ | 13 | -- | Inact |
| M612 | F5c-DArg-hPhe-Arg | Inact | Wk | |
| M676 | DDD-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg) ₂ | -- | -- | |
| M682 | F5c-Lys(F5bz)-Arg | -- | 4.9 | |
| M686 | F5c-NMF-Arg | 29 | 5.6 | |
| M688 | F5c-Dpr(Fbz)-Arg | -- | Inact | |
| M690 | F5c-Dpr(Paa)-Arg | -- | 4.8 | |
| M692 | DDD-(DArg-Arg-Aud-Pac-hPhe-Arg) ₂ | -- | Wk | |
| M696 | F5c-DArg-Eac-2Nal-Arg | Inact | 5.1 | -- |
| M698 | F5c-DArg-Arg-Aud-Pac-2Nal-Arg | 7.1 | Wk | -- |
| M706 | Cin-hPhe-Arg | Inact | Wk | |
| M708 | Ppa-hPhe-Arg | Inact | 5.8 | |
| M710 | DDD-(DArg-Arg-Aud-Pac-2Nal-DArg-NH ₂) ₂ | 1.7 | Wk | |
| M714 | F5c-PCF-Arg | Inact | Wk | |
| M718 | F5c-PFF-Arg | 9 | 5.1 | |
| M720 | F5c-PaF(Ppa)-Arg | Inact | 4.8 | |
| M726 | D-Arg-Arg-Aud-PaF(F5c)-Arg | Inact | 5.6 | |
| M728 | DDD-(DArg-Arg-Aud-PaF(F5c)-Arg) ₂ | 4 | 5.3 | |
| M730 | F5c-DhPhe-Arg | -- | 4.7 | |
| M732 | F5c-PNF-Arg | -- | 4.9 | |
| M734 | DDD-(DArg-Arg-Aud-Pac-PaF(Fbz)-Arg) ₂ | 1.8 | 5.3 | |
| M738 | F5c-DArg-Eac-hPhe-Arg | Inact | 5.3 | |
| M746 | DDD-(Pac-hPhe-Arg) ₂ | Inact | Inact | |
| M752-2 | Pac-hPhe-Arg | Inact | Wk | |
| M752-5 | Aaa-Ser-Pac-hPhe-Arg | Inact | Wk | |
| M752-6 | Aaa-Pac-hPhe-Arg | Inact | Wk | |
| M754 | Aaa-DPhe-hPhe-Arg | Inact | 4.6 | |
| M756 | DDD-(DPhe-hPhe-Arg) ₂ | 18 | 5.2 | |
| M758 | Saa-hPhe-Arg | -- | Wk | |
| M764 | Aaa-DTic-hPhe-Arg | -- | 4.8 | |
| M766 | F5c-DArg-Arg-Aud-DTic-hPhe-Arg | -- | 5.1 | |
| M770 | DDD-(DArg-Arg-Aud-DTic-hPhe-Arg) ₂ | 8 | Inact | |
| M772 | Aaa-DIgl-hPhe-Arg | -- | 4.9 | |
| M774 | F5c-DArg-Arg-Aud-DIgl-hPhe-Arg | 8 | Inact | |
| M776 | DDD-(DIgl-hPhe-Arg) ₂ | 30 | 5 | |
| M778-1 | Pcc-hPhe-Arg | -- | Wk | |
| M780 | Mca-hPhe-Arg | -- | Wk | |
| M782 | Cca-hPhe-Arg | -- | Wk | |
| M784 | Ac-OC2Y-Arg | Inact | Wk | |
| M786 | DDD-(DArg-Arg-Aud-DIgl-hPhe-Arg) ₂ | 3.2 | Wk | |
| M788 | F5c-DArg-Arg-Aud-DTic-Oic-Arg | 9 | 5 | |
| M790 | DDD-(DArg-Arg-Aud-DTic-Oic-Arg) ₂ | 1.7 | Inact | |

| | | | |
|------|--|-------|-------|
| M792 | F5c-DArg-Arg-Eac-Ser-DTic-Oic-Arg | >100 | 4.9 |
| M794 | DDD-(DArg-Arg-Eac-Ser-DTic-Oic-Arg) ₂ | 21 | Inact |
| M796 | F5c-DArg-Arg-Eac-Ser-DF5F-Oic-Arg | 31 | 6.5 |
| M802 | F5c-Lys-Ser-DF5F-Oic-Arg | Inact | 6.3 |
| M804 | DDD-(DArg-Arg-Eac-Ser-DF5F-Oic-Arg) ₂ | 7.3 | 7.7 |
| M806 | Ava-Igl-Ser-DF5F-Oic-Arg | Inact | 5.6 |
| M808 | DDD-(Lys-Ser-DF5F-Oic-Arg) ₂ | 30 | 6.9 |
| M810 | F5c-F5F-Arg | 40 | 4.6 |
| M812 | F5c-PFF-Arg-NH ₂ | 15 | Wk |
| M814 | Ppa-PFF-Arg | Inact | Wk |
| M816 | Dpa-PFF-Arg | 52 | 4.6 |
| M818 | DDD-(DArg-PFF-Arg-NH ₂) ₂ | 60 | Wk |
| M820 | DDD-(DArg-PFF-Arg) ₂ | 43 | Inact |
| M822 | DDD-(DArg-F5F-Arg) ₂ | 25 | Mixed |
| M826 | F5c-MFF-Arg | 76 | Inact |
| M828 | F5c-3,4F2F-Arg | -- | Wk |
| M838 | F5c-DArg-Arg-Aud-DIgl-PFF-Arg | 7.4 | 5.1 |
| M842 | DDD-(DArg-Arg-Aud-DIgl-PFF-Arg) ₂ | 1.4 | Inact |
| M844 | DArg-Arg-Aud-DIgl-PFF-Arg | 12 | Wk |
| M846 | DDD-(DArg-Arg-Aud-DF5F-Oic-Arg) ₂ | 2 | 7.1 |
| M852 | F5c-DArg-Arg-Eac-Ser-DIgl-Oic-Arg | Inact | 5.9 |
| M854 | DDD-(DArg-Arg-Eac-Ser-DIgl-Oic-Arg) ₂ | 7.3 | 5.9 |
| M856 | F5c-DArg-Arg-Aud-Ser-DIgl-Oic-Arg | 21 | 5.4 |
| M858 | DDD-(DArg-Arg-Aud-Ser-DIgl-Oic-Arg) ₂ | 4 | 6.3 |
| M860 | F5c-DArg-Arg-Add-Ser-DIgl-Oic-Arg | 6 | 5.4 |
| M862 | DDD-(DArg-Arg-Add-Ser-DIgl-Oic-Arg) ₂ | 1.3 | 5.6 |
| M864 | DDD-(DArg-Arg-Add-Ser-DIgl-PFF-Arg) ₂ | 1.8 | Inact |
| M868 | Ac-Darg-Arg-Aud-DF5F-Oic-Arg | 55 | 6.5 |
| M888 | F5c-DArg-Arg-Aud-Ser-DF5F-Oic-Arg | 12.5 | 6.6 |
| M890 | DDD-(DArg-Arg-Aud-Ser-DF5F-Oic-Arg) ₂ | 1.7 | 5.5 |
| M922 | DDD-(DNiK-Arg-Eac-Ser-DF5F-Oic-Arg) ₂ | -- | -- |
| M926 | ζ-SUB-(ApC-F5F-Arg) ₂ | Inact | -- |
| M930 | α-DDD-(ApC-F5F-Arg) ₂ | Inact | -- |
| M932 | DDD-(DArg-Arg-Eac-Ser-DIgl-PFF-Arg) ₂ | 6.0 | -- |
| M936 | DDD-(DNiK-PzO-Eac-Ser-DF5F-Oic-Arg) ₂ | -- | -- |
| M944 | DDD-(DArg-Arg-Eac-Ser-DF5F-PFF-Arg) ₂ | 6.7 | -- |
| M946 | F5c-DArg-Arg-Eac-Ser-DF5F-PFF-Arg | -- | -- |
| M950 | α-DDD-(K-DArg-Arg-Eac-Ser-DF5F-Oic-Arg) ₂ | 6.7 | -- |
| M952 | DDD-(DmK-DArg-Arg-Eac-Ser-DF5F-Oic-Arg) ₂ | -- | -- |
| M954 | Aaa-DArg-Arg-Eac-Ser-DF5F-Oic-Arg | 10 | -- |
| M956 | Aaa-DArg-Arg-Aud-Ser-DF5F-Oic-Arg | 14 | -- |
| M958 | F5bz-DArg-Arg-Aud-Ser-DF5F-Oic-Arg | 18 | -- |
| M960 | Aca-DArg-Arg-Aud-Ser-DF5F-Oic-Arg | 21 | -- |
| M964 | 33Dp-DArg-Arg-Aud-Ser-DF5F-Oic-Arg | 4-8 | -- |
| M968 | Dmac-DArg-Arg-Aud-Ser-DF5F-Oic-Arg | 15 | -- |
| M972 | F5pa-DArg-Arg-Aud-Ser-DF5F-Oic-Arg | -- | -- |
| M974 | DDD-(PzO-F5F-Arg) ₂ | -- | -- |
| M976 | DDD-(DNiK-F5F-Arg) ₂ | -- | -- |
| M978 | DDD-(DPzK-F5F-Arg) ₂ | -- | -- |

| | | | |
|-------|---|----|-----|
| M980 | DDD-(DPzO-F5F-Arg) ₂ | -- | -- |
| M1024 | SUB-(DArg-Arg-Eac-Ser-DF5f-Nc7G-Arg) ₂ | 14 | 7.2 |
| M1026 | DTP-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg) ₂ | 70 | 6.9 |
| M1028 | SBEC-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg) ₂ | 28 | 6.7 |
| M1030 | EGS-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg) ₂ | 51 | 7.0 |
| M1034 | DDD-(DArg-F5F-DArg-NH ₂) ₂ | -- | -- |
| M1036 | DDD-(DArg-F5F-DArg) ₂ | 40 | 5.4 |
| M1038 | ε-SUB-(Lys-DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg) ₂ | -- | 6.4 |
| M1042 | Aca-DArg-Arg-Eac-Ser-DF5F-Oic-Arg | -- | -- |
| M1044 | Gun ₂ -BApp-DArg-Arg-Eac-Ser-DF5F-Oic-Arg | -- | -- |
| M1046 | (F5c-DArg-Igl-Arg) ₂ -DDA | -- | -- |

Footnotes:

^a ED₅₀ for killing of SCLC strain SHP-77 *in vitro*, μM.

^b pA₂ for bradykinin antagonist activity on isolated guinea pig ileum. The pD₂ of bradykinin is 7.4 on ileum. Higher numbers indicate higher potency.

^c pA₂ for bradykinin antagonist potency on cloned human B2 receptors, pM. The pD₂ for bradykinin is 11. Higher numbers indicate higher potency.

^d Data included for comparison

Inact = inactive; Mixed = showing both agonist and antagonist activity; Wk = weak

Table 2. ACTIVITIES OF COMPOUNDS NOT RELATED TO BRADYKININ

| NUMBER | STRUCTURE | MTT ^a | GPI ^b | HUMAN ^c |
|----------|--|------------------|------------------|--------------------|
| B9948 | Arg-DNMF-DTrp-Phe-DTrp-Leu | 2.8 | Wk | |
| B10222 | DNMF-DTrp-Phe-DTrp-LeuΨ(CH ₂ NH)Leu-NH ₂ | 6.0 | 5.2 | |
| B10224-1 | α-DDD-(Lys-DNMF-DTrp-Phe-DTrp-LeuΨ(CH ₂ NH)Leu-NH ₂) ₂ | 13 | -- | |
| B10224-2 | α-DDD-(Lys-DNMF-DTrp-Phe-DTrp-LeuΨ(CH ₂ NH)Leu-NH ₂) ₂ | 7 | -- | |
| B10228 | DDD-(DNMF-DTrp-Phe-DTrp-LeuΨ(CH ₂ NH)Leu-NH ₂) ₂ | 40 | Wk | |
| B10242 | Arg-Pro-Lys-Pro-DTrp-Gln-DTrp-Phe-DTrp-LeuΨ(CH ₂ NH)Leu-NH ₂ | 40 | 5.6 | |
| B10244 | DArg-Arg-Pro-Lys-Pro-DTrp-Gln-DTrp-Phe- | 12 | 5.4 | |

| | | | | |
|--------|---|-------|-------|-------|
| B10246 | DTrp-LeuΨ(CH ₂ NH)Leu-NH ₂ DArg-Pro-Lys-Pro-DTrp-Gln-DTrp-Phe-DTrp- LeuΨ(CH ₂ NH)Leu-NH ₂ | 12 | 6.1 | |
| >278 | F5c-Iqa-Atmp | 9 | 5.3 | -- |
| M8 | Gun-Eac-D2Nal-PgF | -- | Inact | |
| M12 | Dcg-Igl-Aqu | 20 | 5.0 | -- |
| M18 | Dcg-2Nal-Aqu | 30 | 6.6 | -- |
| M26 | Gun-2Nal-GaP | -- | 4.9 | |
| M30 | Dcg-2Nal-Apa | -- | 5.4 | |
| M32 | Gun-2Nal-Apa | -- | 4.8 | |
| M36 | Dcg-D2Nal-Apa | -- | 5.0 | |
| M38 | Gun-D2Nal-Apa | -- | 4.9 | |
| M62 | Dcg-2Nal-Ama | -- | 4.8 | |
| M64 | Dcg-2Nal-APa-Sud | -- | Ag | |
| M72-1 | Dcg-Igl-Apa | -- | 4.7 | |
| M72-2 | Dcg-Igl-APa(anisyl) | -- | 4.6 | |
| M76 | Dcg-2Nal- <i>m</i> ABz | -- | 4.9 | |
| M92-1 | Dcg-2Nal- <i>m</i> A ₂ Bz | -- | 5.0 | |
| M92-2 | Dcg-2Nal- <i>m</i> A ₂ Bz(Gun) | -- | 4.8 | |
| M92-4 | Dcg-2Nal- <i>m</i> A ₂ Bz(Dcg) | -- | 5.0 | |
| M104 | Dcg-2Nal-3Pal | -- | 4.9 | |
| M112 | Dcg-D2Nal- <i>m</i> ABz | -- | 5.1 | |
| M120 | Dcg-2Nal- <i>p</i> ABz | -- | 4.7 | |
| M122-1 | Mcg-APa- <i>m</i> ABz | -- | 5.0 | |
| M122-2 | Dcg-APa- <i>m</i> ABz | -- | 4.6 | |
| M136 | Sin-F5F-3Pal | -- | Inact | |
| M162 | Dcg-2Nal-Asp | -- | 4.9 | |
| M168-1 | 2Nap-PaF(Mcg) | -- | 4.8 | |
| M168-2 | 2Nap-PaF(Dcg) | -- | 4.7 | |
| M172 | Inp-Dpr(Dcg-2Nal) | -- | 4.9 | |
| M174 | Dcg-Asp-Aqu | -- | Inact | |
| M180 | F5c- <i>p</i> ABz-2Nal | -- | 5.1 | |
| M188B | Dcg-2Nal-Asp(Aqu) | -- | 5.5 | |
| M202 | F5c-Gly- <i>m</i> ABz-2Nal | -- | 5.1 | |
| M204 | Ac-Pac-Gly- <i>m</i> ABz-Nal | -- | 5.0 | |
| M218 | 2Nal-Atmp | Inact | 4.8 | |
| M222 | Dcg-2Nal-Atmp | 15 | 6.8 | Inact |
| M228-2 | Dcg(Me)-2Nal-Atmp(Me) | 15 | 7.6 | -- |
| M236 | Dcg-Igl-Atmp | >50 | 4.7 | -- |
| M240 | Dcg-F5f-Atmp | 32 | 5.1 | -- |
| M244A | Dcg-2Nal-Atpm | 12 | 5.0 | |
| M244B | Dcg-2Nal-Atpc | Inact | 4.9 | |
| M246 | Dcg-D2Nal-Atmp | >50 | 5.7 | |
| M248 | F5c-2Nal-Atmp | 3.2 | 6.2 | -- |
| M250 | Aca-2Nal-Atmp | -- | 5.2 | |
| M252 | Dhq-2Nal-Atmp | Inact | 4.8 | |

| | | | | |
|--------|--------------------------------------|-------|-------|-------|
| M254 | TDIM-(2Nal-Atmp) ₂ | 5 | 5.1 | -- |
| M254-1 | TDIM-(2Nal-Atmp) ₂ | 5 | 5.1 | |
| M254-2 | TDIM-(2Nal-Atmp) ₂ | 5 | 5.8 | |
| M258 | Dcg-Igl-Atp | -- | 5.0 | |
| M262 | Dcg-D2Nal-Atmp | 6 | 5.3 | |
| M264 | Dcg-Trp-Atmp | 16 | 4.7 | -- |
| M266 | Dcg-Apa-Atmp | 42 | 4.8 | -- |
| M268 | F5c-2Nal-Tpac | 10 | 5.2 | -- |
| M270 | Dcg-2Nal-Tpac | -- | 6.1 | |
| M272 | Dpa-2Nal-Atmp | 9 | 5.2 | -- |
| M274 | Sin-2Nal-Atmp | 36 | 4.7 | -- |
| M276 | Dca-2Nal-Atmp | 4.6 | 5.3 | -- |
| M280 | TDIM-(Igl-Atmp) ₂ | 6 | 5.2 | -- |
| M280-1 | Ctim-Igl-Atmp | 21 | Wk | |
| M280-2 | TDIM-(Igl-Atmp) ₂ | 6 | 5.2 | |
| M286 | Dtp-(2Nal-Atmp) ₂ | 24 | 5.1 | -- |
| M288 | Boc-2Nal-Atmp | Inact | 5.2 | -- |
| M288A | Boc-2Nal-Atmp | >85 | 5.2 | |
| M290-1 | Btac-(2Nal-Atmp) ₂ | >60 | Wk | |
| M290-2 | Btac-(2Nal-Atmp) ₃ | 20 | Wk | |
| M292 | Pac-Igl-Atmp | 40 | Wk | |
| M294 | DDD-(Pac-Igl-Atmp) ₂ | 1.8 | Inact | 10.3 |
| M296 | Pya-Bip-Atmp | 15 | Wk | |
| M302 | Atcp-2Nal-Atmp | 3.5 | 5.2 | |
| M304 | TDIM-(2Nal-Dmm) ₂ | 4.2 | 5.9 | -- |
| M306 | Gbz-2Nal-Atmp | >100 | -- | |
| M308 | Pac-2Nal-Atmp | >75 | 5.0 | |
| M310 | DDD-(Pac-2Nal-Atmp) ₂ | 1.2 | 5.1 | Inact |
| M312 | Tfmc-2Nal-Atmp | 3.2 | 5.5 | -- |
| M314 | F5c-2Nal-Aqd | 25 | 4.6 | |
| M316 | F5c-Tyr-Atmp | 50 | -- | |
| M318 | F5c-Tyr(Bzl)-Atmp | 3.6 | 5.1 | -- |
| M320 | F5c-Oic-Atmp | 13 | -- | -- |
| M322 | F5c-Tic-Atmp | 7.6 | -- | -- |
| M324 | Dmac-2Nal-Atmp | 3 | 5.2 | -- |
| M336-1 | Dcg-2Nal-Asp(R,S)Aqu | -- | 5.1 | |
| M336-2 | Dcg-2Nal-Asp(R,S)Aqu | -- | 5.4 | |
| M340 | Dcg-Pac-Gly-mABz-2Nal | -- | 4.8 | |
| M342 | Dcg-2Nal-Asp-Atmp | -- | 5.4 | |
| M350 | Dcg-2Nal-Glu-Atmp | -- | 5.0 | |
| M354 | Dcg-2Nal-PgF | -- | 5.2 | |
| M362 | Dcg-pAPa-Asp-Atmp | -- | 4.9 | |
| M364 | F5c-pAPa-Asp-Atmp | -- | 4.7 | |
| M368 | Tfmc-pAPa-Asp-Atmp | -- | 4.7 | |
| M396 | F5c-2Nal-Cys(SO ₃ H)-Atmp | -- | 5.0 | |
| M408 | Pya-2Nal-Cyh | 22 | 4.6 | 11.5 |
| M418 | F5c-BtA-Atmp | 3.8 | 7.0 | 10.3 |
| M422 | Pya-pABz-2Nal | 52 | -- | Inact |
| M428 | Pya-Gly-mABz-Aqd | >300 | -- | |
| M430 | DDD-(BtA-Atmp) ₂ | 18 | 5.3 | 11.3 |
| M432 | DDD-(2Nal-Asp-Atmp) ₂ | 70 | -- | 10 |
| M436-1 | TDIM-BtA-Atmp | 8 | 4.8 | |

| | | | | |
|--------|---|-------|-------|-------|
| M436-2 | TDIM-(BtA-Atmp) ₂ | 4.5 | 5.8 | Ag |
| M438 | F5c-3Pal-Atmp | 26 | 4.8 | 10 |
| M440 | Dcg-BtA-Atmp | 30 | -- | |
| M448 | Dmac-BtA-Atmp | 2.7 | 5.7 | Ag |
| M456 | F5c-Cys(Meb)-Atmp | 4.7 | 5.3 | Inact |
| M460 | DDD-(3Pal-Nal-Cyh) ₂ | 15 | Wk | |
| M466 | F5c-2Nal-3Ampy | Inact | Wk | |
| M470 | F5c-2Nal-Ampz | 11 | 5.2 | Inact |
| M472 | Dmac-2Nal-Ampz | 25 | 5.3 | Inact |
| M474 | Pya-2Nal-3Abza | 35 | Wk | Inact |
| M476 | Tha-BtA-Atmp | 15 | 4.6 | Inact |
| M478 | Dmac-2Nal-Thm | 30 | 5.1 | Inact |
| M480-1 | HOOC-DDD-Pac-2Nal-Ampz | 45 | 5.1 | |
| M480-2 | DDD-(Pac-2Nal-Ampz) ₂ | -- | 5.6 | |
| M492 | F5c-mABz-2Nal-Ampz | 45 | 5.1 | Inact |
| M506 | Mse-Pac-BtA-Atmp | 11 | 4.9 | -- |
| M526 | F5c-2Nal-Dmp | 10 | 5.4 | Inact |
| M536 | F5c-2Nal-Dmab | 4 | Wk | Inact |
| M538 | DDD-(Pac-2-Nal-Dmp) ₂ | >80 | Wk | |
| M568 | F5po-2Nal-Atmp | 10 | 5.8 | Ag |
| M570 | F5c-OC2Y-Atmp | 1.8 | 5.6 | Ag |
| M572 | Dca-2Nal-Acep | 2.6 | Wk | Wk |
| M574 | Dns-Tyr(Bzl)Atmp | 4.5 | -- | Inact |
| M582 | Dmac-OC2Y-Atmp | 3 | 5.4 | 9.5 |
| M584-A | DDD-[DArg(Tos)-2Nal-Atmp] ₂ | 5 | Inact | 10.3 |
| M584-B | DDD-(DArg-2Nal-Atmp) ₂ | 5 | 5.7 | 11.3 |
| M586-A | Mse-Pac-Igl-Atmp | 15 | 5.3 | 12 |
| M586-B | Seb-Pac-Igl-Atmp | 40 | Wk | 12.3 |
| M588 | α-DDD-(Lys-DArg-2Nal-Atmp) ₂ | 9.4 | Wk | 10 |
| M592 | F5c-OC2Y-Matp | 1.5 | 4.9 | Ag |
| M594 | F5c-MC2Y-Atmp | 3.7 | 5.0 | 8 |
| M594 | F5c-MC2Y-Atmp | 3.7 | 5.0 | 8 |
| M596-A | DDD-[Arg(Tos)-2Nal-Atmp] ₂ | 15 | 5.0 | |
| M596-B | DDD-(Arg-2Nal-Atmp) ₂ | 8.2 | Wk | Inact |
| M602 | Chc-OC2Y-Atmp | 12 | -- | 10.8 |
| M604 | Pac-2Nal-Ecap | 43 | 4.5 | |
| M606 | DDD-(Pac-2Nal-Api) ₂ | 30 | 5.0 | 10 |
| M614 | F5c-(N-Dmb)-Tyr(Bzl)-OMe | 9.1 | Wk | |
| M616 | DDD-(Pac-1Nal-Atmp) ₂ | 1.4 | 5.4 | -- |
| M618 | F5c-DArg-2Nal-Arg-Matp | 18 | -- | -- |
| M620 | DDD-(DArg-2Nal-Arg-Matp) ₂ | 2.0 | 5.5 | -- |
| M622 | F5c-OC2Y-Mapp | 1.2 | 5.7 | -- |
| M624 | Dns-OC2Y-Matp | 1.4 | 5.1 | -- |
| M626 | Pya-OC2Y-Matp | 3.7 | 4.8 | -- |
| M628 | Cin-OC2Y-Matp | 1.6 | 5.2 | -- |
| M630 | Dmac-OC2Y-Matp | 1.6 | 5.0 | -- |
| M632 | Atcp-OC2Y-Matp | 1.4 | 5.4 | -- |
| M636 | DDD-(DArg-Arg-Aud-Pac-2Nal-Atmp) ₂ | 1.7 | 5.8 | -- |
| M638 | DDD-(DArg-Igl-Arg-Matp) ₂ | 0.6 | Inact | |
| M640 | DDD-(DArg-BtA-Arg-Matp) ₂ | 3.0 | 5.9 | |
| M648 | F5c-PaF(Mes)-Atmp | Inact | 5.0 | |
| M650 | Atcp-OC2Y-Mapp | 3.7 | -- | -- |

| | | | | |
|--------|---|-------|-------|----|
| M652 | Ppa-OC2Y-Mapp | 7.5 | 5.7 | -- |
| M654 | Sul-Atmp | Inact | 4.5 | |
| M656 | Sul-2Nal-Atmp | 13 | 5.4 | |
| M660 | DDD-(His-1Nal-Atmp) ₂ | 30 | Wk | -- |
| M662 | F5c-tLeu-Atmp | Inact | 5.2 | -- |
| M664 | F5c-OC1Y-Matp | 1.2 | 5.0 | |
| M666 | Dns-OC1Y-Matp | 1.3 | 5.0 | |
| M668 | SBEC-(DArg-2Nal-Arg-Matp) ₂ | 3.4 | 5.2 | |
| M670 | DTP-(DArg-Igl-Arg-Matp) ₂ | Inact | 5.1 | |
| M672 | HDD-(DArg-Igl-Arg-Matp) ₂ | -- | -- | |
| M674 | DDD-(DArg-F5F-Arg-Matp) ₂ | 3.5 | Wk | |
| M678 | (Dns-DArg-Igl-Arg) ₂ -DDA | 1.1 | 5.3 | |
| M724 | F5c-DArg-Aud-OC2Y-Gly-Atmp | 12 | 5.4 | |
| M744 | DDD-(DArg-2Nal-Arg-Dmab) ₂ | 3.4 | 5.3 | |
| M798 | F5c-OC2Y-Dmab | 37 | -- | |
| M800 | DDD-(DArg-OC2Y-Dmab) ₂ | 27 | 5.3 | |
| M832 | F5c-PFF-Dmab | 47 | 4.6 | |
| M834 | DDD-(DArg-PFF-Arg-Dpea) ₂ | 1.6 | 5.3 | |
| M848 | DDD-(DArg-F5F-Arg-Dmab) ₂ | -- | -- | |
| M880 | DDD-(DArg-F5F-Arg-Dpea) ₂ | -- | -- | |
| M886-1 | DDD-DArg-PFF-Arg-NH ₂ L-DArg-PFF-Arg-Dpma | 3.2 | Wk | |
| M886-2 | DDD-(DArg-PFF-Arg-Dpma) ₂ | -- | Inact | |
| M892 | DDD-(DArg-PFF-Arg-PFF-NH ₂) ₂ | 8.5 | Wk | |
| M900 | DDD-(DArg-F5F-Arg-PaF-NH ₂) ₂ | 6.3 | -- | |
| M916 | F5c-DArg-PFF-Arg-PFF-NH ₂ | 5.7 | 4.9 | |
| M1032 | DDD-(DArg-Igl-Mapp) ₂ | 15 | 5.4 | |
| M1040 | EDTA-(OC2Y-Atmp) ₄ | 0.73 | -- | |

Footnotes:

^aED₅₀ for killing of SCLC strain SHP-77 *in vitro*, μM.

^bpA₂ for bradykinin antagonist activity on isolated guinea pig ileum. The pD₂ of bradykinin is 7.4 on ileum. Higher numbers indicate higher potency.

^cpA₂ for bradykinin antagonist potency on cloned human B2 receptors, pM. The pD₂ for bradykinin is 11. Higher numbers indicate higher potency.

Ag = agonist; Inact = inactive; Wk = weak

5 Table 3. ACTIVITIES OF CYCLIC PEPTIDES

| NUMBER | STRUCTURE | MTT ^a | GPI ^b |
|---------|---|------------------|------------------|
| B9458-2 | DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-CpGΨ(CH ₂ N)Arg _____CO_____CH ₂ _____/ \\ CH ₂ CO ₂ H | -- | 6.1 |
| B9462 | Darg-Arg-Pro-Hyp-Gly-Thi-Ser-Digl-CpGΨ(CH ₂ N)Arg _____CO_____CH ₂ _____/ \\ CH ₂ CO ₂ H | 7.3 | 6.0 |
| B10302 | c[DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg] | Inact | 5.2 |
| B10304 | Aca-c[DArg-Arg-Pro-Hyp-Gly-Thi-Ser-Nig-Oic-Arg] | Inact | 6.4 |
| B10306 | c[Arg-DNMF-DTrp-Phe-DTrp-Leu] | Inact | Wk |
| B10312 | α-DDD-(c[Lys-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DF5F-Oic-Arg]) ₂ | 3.8 | -- |
| M680 | c[DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg] | -- | -- |
| M824 | c[Ava-Igl-Ser-DF5F-Oic-Arg] | Inact | 5.2 |
| M850 | c[DArg-Arg-Aud-DIgl-PFF-Arg] | 1.4 | 5.1 |
| M868-2 | c[DArg-Arg-Aud-DF5F-Oic-Arg] | 9.2 | 6.1 |
| M870 | c[DArg-Arg-Add-DF5F-Oic-Arg] | 5.5 | 5.3 |
| M872 | c[DArg-Arg-Eac-Ser-DF5F-Oic-Arg] | 2.2 | Inact |
| M874 | c[DArg-Arg-Add-Ser-DF5F-Oic-Arg] | 11 | 5.0 |
| M876 | c[DArg-Arg-Aud-Ser-DF5F-Oic-Arg] | 22.5 | 5.4 |
| M878 | c[DArg-Arg Add-DIgl-PFF-Arg] | 7 | Wk |
| M882 | c[DArg-Arg-Add-Ser-DIgl-PFF-Arg] | 4.5 | Inact |
| M896 | c[DArg-Arg-Eac-DIgl-PFF-Arg] | 65 | Wk |
| M902 | c[DArg-Arg-Ava-Ser-DIgl-PFF-Arg] | 30 | 5.5 |
| M906 | c[DArg-Arg-Eac-DF5F-Oic-Arg] | 45 | Wk |
| M908 | c[DArg-Arg-Ava-Ser-DF5F-Oic-Arg] | 40 | 4.9 |
| M910 | c[Bala-DArg-Arg-Eac-Ser-DF5F-Oic-Arg] | 42 | 5.2 |
| M924 | c[Suc-DArg-Arg-Eac-Ser-DIgl-PaF]-Arg | 37 | Wk |
| M934 | c[DNiK-Arg-Eac-Ser-DF5F-Oic-Arg] | -- | -- |
| M940 | c[DNiK-PzO-Eac-Ser-DF5F-Oic-Arg] | -- | -- |
| M986 | c[Add-DArg-F ₃ F-Arg] | -- | -- |

Footnotes:

10 ^aED₅₀ for killing of SCLC strain SHP-77 *in vitro*, μM.

^bpA₂ for bradykinin antagonist activity on isolated guinea pig ileum. The pD₂ of bradykinin is 7.4 on ileum. Higher numbers indicate higher potency.

Inact = inactive; Wk = weak

Table 4. PREVIOUSLY DESCRIBED KNOWN PEPTIDES THAT NEWLY SHOW *IN VIVO* ANTI-CANCER ACTIVITY

NUMBER STRUCTURE

| | |
|--------|--|
| B9430 | DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg |
| B9330 | DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg |
| B10044 | DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg |
| B10050 | Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG |
| B10206 | DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg |
| B10288 | DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg |

10 These compounds showed anti-tumor activity *in vivo* when tested by the procedure of Example XXI.

TABLE 5. CYTOTOXICITY *IN VITRO* AGAINST STRAINS OF PROSTATE CANCER

| COMPOUND NUMBER | PROSTATE CANCER CELL LINE | | | | | SCLC |
|--------------------|---------------------------|-----|------|------|------|------|
| | DU14 | TSU | LNCa | PC-3 | PPC1 | |
| B9870 | 0.08 | 6.5 | 3.7 | 3.2 | 4.3 | 0.15 |
| M570 | 1.2 | 2.8 | 3.0 | 1.6 | 3.0 | 1.8 |
| M590 | 0.01 | 7.0 | 7.0 | 6.3 | 12 | 4.5 |

Numbers are ED₅₀ (μM) for cytotoxic activity. Activity against SCLC strain SHP-77 is included for comparison.

TABLE 6. ABBREVIATIONS USED FOR COMPOUNDS

B9430 = DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg
 B9870 = SUIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg)₂
 Aaa = 1-Adamantaneacetyl
 AAA = amino acid analysis
 ABz = Aminobenzoic acid
 ABza = Aminobenzyl alcohol
 Ac = Acetyl
 Ac3c = 1-Amino-1-cyclopropanecarboxylic acid
 Ac5c = 1-Amino-1-cyclopentanecarboxylic acid ("cyclo-Leu")
 Ac6c = 1-Aminocyclohexanecarboxylic acid
 Aca = 1-Adamantanecarboxyl
 Acep = 4-Amino-1-carbethoxymethyl-2,2,6,6-tetramethylpiperidine
 ADA = 1,3-Adamantanediacyl

Add = 12-Aminododecanoic acid
 Aib = α -Aminoisobutyric acid
 Aic = 2-Aminoindane-2-carboxylic acid
 AlG = α -Allylglycine (2-amino-4-pentenoic acid)
 Ama = Aminomethylantranilic acid
 Amb = Aminomethylbenzoic acid
 Ampy = 3-Aminomethylpyridine
 Ampz = 1-Amino-4-methylpiperazine
 Ana = Anthranilic acid
 APa = *p*-Aminophenylacetic acid
 APb = *p*-Aminophenylbutyric acid
 ApC = S-3-Aminopropylcysteine
 Api = 4-Aminopiperidine
 Apmp = 4-Amino-1,2,2,6,6-pentamethylpiperidine
 Aptp = 4-Amino-1-phenylmethyl-2,2,6,6-tetramethylpiperidine
 Aqd = 4-Aminoquinaldine
 Aqu = 3-Aminoquinuclidine
 Arg(NO₂) = Arginine(Nitro)
 Atc = 2-Aminotetralin-2-carboxylic acid
 Atcp = 4-Amino-3,5,6-trichloropicolinic acid
 Atmp = 4-Amino-2,2,6,6-tetramethylpiperidine
 AtmpO = 4-Amino-2,2,6,6-tetramethylpiperidinyloxy
 Atpc = 4-Amino-2,2,6,6-tetramethyl-4-piperidinecarboxylic acid
 Atpm = 4-Amino-4-methoxycarbonyl-2,2,6,6-Tetramethylpiperidine
 (4-Amino-2,2,6,6-tetramethyl-4-piperidinecarboxylic acid methyl
 ester)
 Aud = 11-Aminoundecanoic acid
 Ava = 5-Aminovaleric acid
 Azt = Azetidine-2-carboxylic acid
 BAla = β -Alanine
 BApG = N,N-*bis*(3-aminopropyl)-glycine
 BAPTA = 1,2-*bis*(2-Aminophenoxy)ethane-N,N,N',N'-tetraacetyl
 Bip = Biphenylalanine
 Boc = (*tert*-Butoxycarbonyl); [(1,1-dimethylethoxy)carbonyl]
 BOP = Benzotriazoyloxytris(dimethylamino)phosphonium
 hexafluorophosphate
 BPHD = N,N'-*bis*(2,2,6,6-tetramethyl-4-piperidinyloxy)-1,6-hexanediamine
 BSH = 1,6-Bissuccinimidohexane
 BtA = 3-Benzothienylalanine
 BTAC = Benzene-1,3,5-*tris*-carboxamido-6-caproyl
 BTC = 1,3,5-Benzenetricarboxyl

Bz = Benzoyl
 Bzl = Benzyl
 CAcH = *cis*-2-Amino-1-cyclohexanecarboxylic acid
 Cca: 2-Chlorocinnamic acid
 CDF = *p*-Chloro-D-phenylalanine
 ChA = α -Cyclohexylalanine
 Chc = α -Cyano-4-hydroxycinnamoyl
 ChG = α -Cyclohexylglycine
 CHO = Chinese hamster ovary
 CHTC = 1,3,5-Cyclohexanetricarboxyl
 CHyp = *cis*-4-Hydroxy-proline
 Cin = Cinnamoyl
 CMeb = S-(4-Methylbenzyl cysteine
 CmF = (Z) *p*-Chloro-2,3-methanophenylalanine
 Cmp = 4-Carboxymethylpiperazine
 CpA = α -Cyclopropylalanine
 CpG = α -Cyclopentylglycine
 CpG Ψ (CH₂N)Arg = CpG pseudo(CH₂NH) Arg
 CPTA = *trans*-1,2-Diaminocyclohexane- N,N,N',N'-tetraacetyl
 CTAC = Cyclohexane-1,3,5-*tris*-carbamido- ϵ -caproyl
 Ctim = 13-Carboxytridecanimidyl
 Cyh = Cyclohexylamine
 Dabz = Diaminobenzoic acid
 DArg(NO₂) = Nitro-Arginine
 Dca = Dicyclohexylacetyl
 Dcg = N,N'-Dicyclohexylguanidyl
 DCM = Dichloromethane
 DDA = 1,10-Decanediamine
 DDD = Dodecanedioyl
 DDS = 2-Dodecen-1-ylsuccinyl
 DEA = N,N'-Diethylethylenediamine
 DhP = 3,4-Dehydroproline
 Dhq = 2,3-Dehydroquinuclidine-3-carboxyl
 DIC = Decahydroisoquinoline-3-carboxylic acid
 DIEA = Diisopropylethylamine
 Dmab = 4-Dimethylaminobenzylamine
 Dmac = 4-Dimethylaminocinnamoyl
 Dmb = 4-(Dimethylamino)benzyl
 DmF = 2,4-Dimethylphenylalanine
 DMF = Dimethyl formamide
 DmK = ϵ -Dimethyllysine

Dmm = 2,6-Dimethylmorpholine
 Dmp = 3-Dimethylaminopropylamine
 DmtP = 5,5-Dimethyl-4-thiaproline
 Dns = Dansyl (5-dimethylamino-1-naphthalenesulfonyl)
 22Dp = 2,2-Diphenylpropionyl
 33Dp = 3,3-Diphenylpropionyl
 Dpa = Diphenylacetyl
 Dpea = Diphenylethylamine
 Dpma = Diphenylmethylamine
 Dpr = 2,3-Diaminopropionic acid
 DTP = Dithiobis-propionyl
 DTPA = Diethylenetriaminepentaacetyl
 Eac = ϵ -Aminocaproic acid
 Ecap = N-Ethoxycarbonyl-4-amino-piperidine (Ethyl 4-amino-1-piperidinecarboxylate)
 EDA = 4,4'-Ethylenedianiline
 EDP = 4,4'-Ethylenedipiperidine
 EDTA = Ethylenediaminetetraacetyl
 EDTP = Ethylenediaminetetrapropionic acid
 EGS = Ethylene glycol-*bis*-succinyl
 EGTA = Ethylene glycol-*bis*-(β -aminoethyl ether)- N,N,N',N'-tetraacetyl
 EOPC = 1,1'-Ethylenebis(5-oxo-3-pyrrolidinecarboxyl)
 ETTA = 2,2',2'',2'''-[Ethanediylidenetetrakis(thio)tetrakisacetyl
 F2F = Difluorophenylalanine
 F5bz = Pentafluorobenzoyl
 F5c = 2,3,4,5,6-Pentafluorocinnamoyl
 F5F = Pentafluorophenylalanine
 F5pa = 2,3,4,5,6-Pentafluorophenylacetyl
 F5po = 2,3,4,5,6-Pentafluorophenoxyacetyl
 Fbz = *para*-Fluorobenzoyl
 Flu = Fluorescein thiourea
 Gaa = Guanidinoacetyl
 GaP = 2-Guanidyl-3-(4-aminophenyl)propionic acid
 Gbz = 4-Guanidinobenzoyl
 Glt = Glutaryl
 Gun = Guanidyl
 HATU = O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
 HbQ = 4-Hydroxybutylglutamine
 HDA = 1,6-Hexanediamine
 HDD = Hexadecanedioyl

HF = Hydrogen fluoride
 HFG = Hexafluoroglutaroyl
 HiG = Hexahydro-2-indanylglycine
 HOAt = 1-Hydroxy-7-azabenzotriazole
 hPhe = Homo-phenylalanine
 HPLC = high performance liquid chromatography
 Hxa = Hexanoic acid
 Hyp = *trans*-4-Hydroxyproline
 Ica = Indoline-2-carboxylic acid
 Igl = α -2-Indanylglycine
 Ing = α -1-Indanylglycine
 Inp = Isonipecotic acid
 Iq2a = 6,7-Dimethoxy-3,4-dihydro-1-isoquinolineacetic Acid
 Iq4a = 6,7-Dimethoxy-1,2,3,4-tetrahydro-1-isoquinolineacetic acid
 Lau = Lauroyl
 Leu(r)Leu = Leu-pseudo(CH₂NH)Leu
 Leu Ψ (CH₂NH)Leu = Leu-pseudo(CH₂NH)Leu
 LDMS = laser desorption mass spectrometry
 mA₂Bz = 3,5-Diaminobenzoic acid
 MaG = α -Methallylglycine (2-amino-3-methyl-4-pentenoic acid)
 Mapp = 4-(Methylamino)-1,2,2,6,6-pentamethylpiperidine
 Matp = 4-(Methylamino)-2,2,6,6-tetramethylpiperidine
 MatpO = 4-(N-methylamino)-2,2,6,6-tetramethylpiperidinyloxy
 MBC = S-(4-methylbenzyl)cysteine
 MBHA = Methylbenzhydramine
 MC2Y = N-Methyl-O-2,6-dichlorobenzyl-tyrosine
 Mca = 2-Methylcinnamic acid
 Mcg = Monocyclohexylguanidyl
 Meb = Methylbenzyl
 MeP = 2,4-Methanoproline
 Mes = Methanesulfonyl
 MFE = (E)-2,3-Methanophenylalanine
 MFF = *meta*-Fluorophenylalanine
 Mosi = Methoxy-suberimido
 Moti = 14-Methoxytetradecanediimidoyl
 Mse = Methoxysebacyl
 MTT = (3-(4,5)-Dimethyltriazol-2-yl)-2,5-diphenyl tetrazolium bromide
 Nal = β -Naphthylalanine
 Nap = Naphthoyl
 Nba = Norbornane-2-acetyl
 Nbc = Norbornenedicarboxyl

Nbi = Norbornenedicarboximide
 Nbn = 2-Aminonorbornane-2-carboxylic acid
 Nc5G = N-Cyclopentylglycine
 Nc6G = N-Cyclohexylglycine
 Nc7G = N-Cycloheptylglycine
 Nc8G = N-Cyclooctylglycine
 Nig = N-2-Indanylglycine
 NiK = ϵ -Nicotinoyllysine
 NMF = N-Methylphenylalanine
 NSCLC = non-small cell carcinoma
 OBS = O-Benzylserine
 OBT = O-Benzylthreonine
 OBY = O-Benzyltyrosine
 OC2Y = O-2,6-Dichlorobenzyltyrosine
 OC1Y = O-2,6-Dichlorobenzyl-3,5-diiodotyrosine
 Oct = Octanoyl
 Oic = Octahydroindole-2-carboxylic acid
 OMe = O-Methyl
 OMY = O-Methyltyrosine
 OSY = Tyrosine O-sulfate ester
 Paa = Phenylacetyl
 Pac = 4-Aminocinnamic acid
 PaF = *p*-Aminophenylalanine
 Pal = β -Pyridylalanine
 Pba = Phenylbutyryl
 Pcc = *trans*-2-Phenyl-1-cyclopropanecarboxylic acid
 PCF = *p*-Chlorophenylalanine
 Pcpa = α -Phenylcyclopentaneacetyl
 PdF = *p*-Dicyclohexylguanidylphenylalanine
 PFF = *p*-Fluorophenylalanine
 PFS = Perfluorosuberoyl
 PgF = *p*-Guanidinophenylalanine
 PheOL = Phenylalaninol
 PhG = Phenylglycine
 Pip = Pípecolic acid ("homo-Pro")
 PipA = β -3-Piperidylalanine
 PNF = *p*-Nitrophenylalanine
 Ppa = Phenylpropionyl
 Pya = *trans*-3-(3-Pyridyl)acryloyl
 PyAOP = 7-Azabenzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate

PzK = ϵ -Pyrazinoyllysine
 PzO = 4-Pyrazinoylornithine 4-(2-pyrazin carboxyl) orn
 Saa = *trans*-Styrylacetic acid
 SBEC = Sulfo-*bis*-ethoxycarbonyl
 Sbl = Sebacoyl
 SCLC = small cell lung carcinoma
 Seb = Sebacyl
 Sin = Sinapyl (3,5-dimethoxy-4-hydroxycinnamoyl-)
 Ste = Stearoyl
 Sua = Sulfanilamide (4-Aminobenzenesulfonamide)
 SUB = Suberyl
 Suc = Succinyl
 Sud = Sulfadiazine
 SUIM = Suberimidyl
 Sul = Sulindac
 Tba = *t*-Butyl-acetyl
 TDIM = Tetradecanediimidyl
 TEA = Triethylamine
 TFA = Trifluoroacetic acid
 Tfmc = *trans*-4-(Trifluoromethyl)cinnamoyl
 Tha = 3-(2-Thienyl)acryloyl
 Thi = β -2-Thienylalanine
 Thm = Thiomorpholine
 Thz = Thiazolidine-4-carboxylic acid (4-thiaproline)
 Tic = 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid
 TLC = thin layer chromatography
 TLeu = *tert*-Leucine
 TMF = 2,4,6-Trimethylphenylalanine
 Tos = *p*-Toluenesulfonyl
 Tpac = 2,2,5,5-Tetramethyl-3-(aminoethyl)-pyrroline-3-carboxamide
 TREN = *tris*(2-Aminoethyl)amine
 Trx = Tranexamic acid (*trans*-4-((Aminomethyl))cyclohexanecarboxylic acid)